^
Association details:
| Biomarker: | CDA underexpression + SLC29A1 overexpression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | gemcitabine (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
Published date:
11/17/2021
Excerpt:
Gemcitabine or 5-fluorouracil (5-FU) based treatments can be selected for pancreatic cancer....Analysis of both CDA and hENT1 was possible with 277 patients....With gemcitabine, patients expressing low CDA mRNA with high hENT1 protein have the longest overall median survival of 28.0 (95% CI = 21.1–45.5) months compared with 23.8 (95% CI = 16.6−28.7) months in patients with high hENT1 protein and high CDA mRNA.
DOI:
10.3390/cancers13225758
